135 related articles for article (PubMed ID: 15305155)
1. Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients.
Murer K; Urosevic M; Willers J; Selvam P; Laine E; Burg G; Dummer R
Melanoma Res; 2004 Aug; 14(4):257-62. PubMed ID: 15305155
[TBL] [Abstract][Full Text] [Related]
2. Expression of melanoma-associated antigens in melanoma cell cultures.
Urosevic M; Braun B; Willers J; Burg G; Dummer R
Exp Dermatol; 2005 Jul; 14(7):491-7. PubMed ID: 15946236
[TBL] [Abstract][Full Text] [Related]
3. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens.
van Dinten LC; Pul N; van Nieuwpoort AF; Out CJ; Jager MJ; van den Elsen PJ
Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):24-30. PubMed ID: 15623750
[TBL] [Abstract][Full Text] [Related]
4. MART-1/Melan-A and tyrosinase transcripts in peripheral blood of melanoma patients: PCR analyses and follow-up testing in relation to clinical stage and disease progression.
Strohal R; Mosser R; Kittler H; Wolff K; Jansen B; Brna C; Stingl G; Pehamberger H
Melanoma Res; 2001 Oct; 11(5):543-8. PubMed ID: 11595894
[TBL] [Abstract][Full Text] [Related]
5. Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells.
Schrader AJ; Probst-Kepper M; Grosse J; Kunter U; Schenk F; Franzke A; Atzpodien J; Buer J
Melanoma Res; 2000 Aug; 10(4):355-62. PubMed ID: 10985670
[TBL] [Abstract][Full Text] [Related]
6. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
7. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.
Xu X; Chu AY; Pasha TL; Elder DE; Zhang PJ
Am J Surg Pathol; 2002 Jan; 26(1):82-7. PubMed ID: 11756773
[TBL] [Abstract][Full Text] [Related]
8. Expression of S100a, vimentin, NSE, and melan A/MART-1 in seven canine melanoma cells lines and twenty-nine retrospective cases of canine melanoma.
Koenig A; Wojcieszyn J; Weeks BR; Modiano JF
Vet Pathol; 2001 Jul; 38(4):427-35. PubMed ID: 11467477
[TBL] [Abstract][Full Text] [Related]
9. Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.
Ramirez-Montagut T; Andrews DM; Ihara A; Pervaiz S; Pandolfi F; Van Den Elsen PJ; Waitkus R; Boyle LA; Hishii M; Kurnick JT
Clin Exp Immunol; 2000 Jan; 119(1):11-8. PubMed ID: 10606959
[TBL] [Abstract][Full Text] [Related]
10. Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions.
Butterfield LH; Stoll TC; Lau R; Economou JS
Gene; 1997 Jun; 191(2):129-34. PubMed ID: 9218710
[TBL] [Abstract][Full Text] [Related]
11. Melanoma-associated antigens as messenger RNA detection markers for melanoma.
Sarantou T; Chi DD; Garrison DA; Conrad AJ; Schmid P; Morton DL; Hoon DS
Cancer Res; 1997 Apr; 57(7):1371-6. PubMed ID: 9102226
[TBL] [Abstract][Full Text] [Related]
12. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
[TBL] [Abstract][Full Text] [Related]
13. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies.
Dalerba P; Ricci A; Russo V; Rigatti D; Nicotra MR; Mottolese M; Bordignon C; Natali PG; Traversari C
Int J Cancer; 1998 Jul; 77(2):200-4. PubMed ID: 9650552
[TBL] [Abstract][Full Text] [Related]
14. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma.
Berset M; Cerottini JP; Guggisberg D; Romero P; Burri F; Rimoldi D; Panizzon RG
Int J Cancer; 2001 Jan; 95(1):73-7. PubMed ID: 11241315
[TBL] [Abstract][Full Text] [Related]
15. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
Melanoma Res; 1998 Aug; 8(4):337-43. PubMed ID: 9764809
[TBL] [Abstract][Full Text] [Related]
16. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis.
El Shabrawi-Caelen L; Kerl H; Cerroni L
Am J Dermatopathol; 2004 Oct; 26(5):364-6. PubMed ID: 15365366
[TBL] [Abstract][Full Text] [Related]
17. Detection of circulating melanoma cells by a two-marker polymerase chain reaction assay in relation to therapy.
Bitisik O; Camlica H; Duranyildiz D; Tas F; Kurul S; Dalay N
J Biochem Mol Biol; 2003 Mar; 36(2):173-8. PubMed ID: 12689515
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled--polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma.
Brownbridge GG; Gold J; Edward M; MacKie RM
Br J Dermatol; 2001 Feb; 144(2):279-87. PubMed ID: 11251559
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.
Reynolds SR; Oratz R; Shapiro RL; Hao P; Yun Z; Fotino M; Vukmanović S; Bystryn JC
Int J Cancer; 1997 Sep; 72(6):972-6. PubMed ID: 9378560
[TBL] [Abstract][Full Text] [Related]
20. Development of a multiple-marker polymerase chain reaction assay for detection of metastatic melanoma in lymph node aspirates of dogs.
Catchpole B; Gould SM; Kellett-Gregory LM; Dobson JM
Am J Vet Res; 2003 May; 64(5):544-9. PubMed ID: 12755292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
